Close

NeuroDerm (NDRM) Says ND0612H Phase II Trial Results to be Presented in Late-Breaking Session at MDS Congress

May 23, 2017 7:11 AM EDT Send to a Friend
NeuroDerm Ltd. (Nasdaq: NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS) disorders, today announced ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login